Evidence map›Paper›PMID 40162234›Full record

ArticleResearch square2025

A Novel Mouse Model of Type 2 Diabetes Using a Medium-Fat Diet, Fructose, and Streptozotocin to Study the Complications of Human Disease.

Yanina Luciana Mazzocco, Gastón Bergero, Sebastián Del Rosso, Zoé M Cejas Gallardo, Alejandra Canalis, Ruth Eliana Baigorri, Luciana Mezzano, Juan Javier Mladin, Gustavo Tomas Diaz, Claudia Erika Martinez and 2 more

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Yanina Luciana MazzoccoConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI).
Gastón BergeroConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI).
Sebastián Del RossoConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI).
Zoé M Cejas GallardoConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI).
Alejandra CanalisConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI).
Ruth Eliana BaigorriConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI).
Luciana MezzanoInstituto de Biología Celular, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba.
Juan Javier MladinHospital Nuestra Señora de la Misericordia-Nuevo Siglo.
Gustavo Tomas DiazInstituto de Biología Celular, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba.
Claudia Erika MartinezHospital Nuestra Señora de la Misericordia-Nuevo Siglo.
Roxana Carolina CanoConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI).
Maria Pilar AokiConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI).

Funding

Targeting purinergic signaling in Chagas diseaseR01AI176457 · NIAID · NATIONAL RESEARCH COUNCIL OF ARGENTINA · PI Maria Pilar Aoki · 2023 to 2026
$525k
NIAID NIH HHS R01 AI176457
6 · The paper itself

Abstract

The study of type 2 diabetes mellitus (T2DM) pathophysiology relies mainly on the use of animal models, the most common of which involves the consumption of high-fat diets comprising 60% calories from fat. Although these models reproduce the onset and most complications associated with T2DM, they do not accurately mimic human dietary patterns, as they lack the addition of carbohydrates such as fructose. This study aimed to develop a C57BL/6 mouse model of T2DM that mimics the disease, as occurs in younger individuals, via a medium-fat diet (34.5% kcal from fat) combined with a 20% fructose solution as drinking water and a single low-dose of streptozotocin (STZ) (100 mg/kg), a diabetogenic drug. At week 20, D + T mice exhibited significant weight gain and elevated fasting blood glucose levels compared with those of control mice and the development of insulin resistance. Similarly, the circulating levels of hepatic enzymes (GPT, GOT, and alkaline phosphatase), total cholesterol, and LDL increased. Multi-organ damage, including reduced pancreatic islet size and number, severe hepatic steatosis, inflammatory infiltration in visceral adipose tissue, and cardiac and renal dysfunction, were also detected. The proposed model replicates T2DM in young mice by combining a medium-fat diet with fructose and STZ.

Identifiers

PMID40162234
PMCPMC11952668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.